{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-097180","form_type":"8-K","ticker":"BCLI","cik":"0001137883","company_name":"BRAINSTORM CELL THERAPEUTICS INC.","filed_at":"2026-08-14T20:16:35+00:00","discovered_at":"2026-08-14T20:25:00.528304+00:00","generated_at":"2026-08-14T20:25:19.719046+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BrainStorm Q2 2026 net loss $3.9M, cash down to $0.2M; advances NurOwn Phase 3b","bullets":["Q2 2026 net loss $3.9M vs $2.9M in Q2 2025; EPS -$0.35 vs -$0.34.","Cash, equivalents, restricted cash $0.2M at June 30, 2026, down from $1.03M a year earlier.","G&A jumped to $2.7M from $1.5M; R&D was ~$1.0M vs $1.1M.","Phase 3b ENDURANCE trial of NurOwn in ALS planned for ~200 patients under FDA SPA; Peter Pitts named Executive Chairman.","Raised $400k in May 2026 private placement; H1 2026 total capital ~$2.4M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-097180","json":"https://secwatch.observer/filing/0001104659-26-097180.json","markdown":"https://secwatch.observer/filing/0001104659-26-097180.md","text":"https://secwatch.observer/filing/0001104659-26-097180.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1137883/000110465926097180/0001104659-26-097180-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1137883/000110465926097180/tm2623188d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T20:25:19.719046+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}